Navigation Links
NewCardio Announces Master Services Agreement With Dedicated Phase I
Date:8/5/2009

SANTA CLARA, Calif., Aug. 5 /PRNewswire-FirstCall/ -- NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that Dedicated Phase I, an innovative, Phoenix, Arizona-based provider of clinical research services including a Core ECG laboratory for Thorough QT and QTc studies, has signed a Master Services Agreement (MSA) with NewCardio. Under terms of this agreement, Dedicated Phase I will receive a license to use NewCardio's QTinno(TM) software solution in all TQT studies where fully automated readings are obtained.

It is anticipated that Dedicated Phase I, by utilizing QTinno(TM) in addition to its existing infrastructure, will be able to deliver the full range of TQT/QTc studies, becoming a turnkey provider of these studies to its customers.

Jason Bonanza, President and CEO of Dedicated Phase I, commented, "We are excited to add NewCardio's QTinno(TM) solution to our advanced Core ECG laboratory. By integrating this important technological advancement with our existing solutions, we can deliver TQT/QTc studies for upload to the FDA digital ECG warehouse with greater accuracy and lower intrinsic variability than the legacy manual or semi-automated methodologies provide. In addition, we can reduce study timelines by several weeks, providing significant savings to customers on the overall cost of the study. The net result is that sponsors will receive higher quality study results and also save time and money. This is a win-win for Dedicated Phase I and our customers."

"This agreement will enable Dedicated Phase I to deliver quality TQT/QTc studies to its customers, to include both CROs and sponsors, with higher accuracy and lower variability in a more timely and cost-effective manner," said Vincent Renz, NewCardio's President and Chief Operating Officer. "Dedicated Phase I is truly an innovative organization, and this agreement demonstrates the firm's commitment to the use of technology to improve quality and efficiency."

This Master Services Agreement is part of a transition from semi-automated methods to more advanced, higher quality, and more efficient methodologies made possible for the first time through the use of NewCardio's QTinno(TM) solution.

NewCardio's innovative 3D ECG platform technology dramatically improves the accuracy and significantly increases the diagnostic value of the standard 12-lead electrocardiogram (ECG). NewCardio's lead product is QTinno(TM), a software suite that provides an automated, comprehensive analysis of QT intervals and other ECG-based cardiac safety for the pharmaceutical industry and drug regulators. The Company believes that its QTinno(TM), software-based, analytical technology is the industry's first solution for the reliable automated analysis of ECGs used to determine cardiac toxicity during drug development.

About NewCardio, Inc.

NewCardio is a cardiac diagnostic and services company focused on the development of a proprietary platform technology to provide higher accuracy to, and increase the value of, the standard 12-lead electrocardiogram (ECG). NewCardio's development-stage software and hardware products and services are intended to improve the diagnosis and monitoring of cardiovascular disease (CVD), as well as cardiac safety assessment of drugs under development. NewCardio's three-dimensional ECG platform is designed to reduce the time and expense involved in assessing cardiac status while increasing the ability to diagnose clinically significant conditions which were previously difficult to detect. For more information, visit www.newcardio.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions. These statements are based on current expectations, estimates and projections about our business based on currently available information and assumptions made by management. Although we believe that the assumptions on which the forward-looking statements contained herein are based are reasonable, any of those assumptions could prove to be inaccurate given the inherent uncertainties as to the occurrence or nonoccurrence of future events. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2008 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. Information concerning factors that could cause our actual results to differ materially from these forward-looking statements can be found in our periodic reports filed with the Securities and Exchange Commission. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

    Investor Contact:
    Hayden IR
    Jeff Stanlis, Partner and VP of Communications
    (602)476-1821
    jeff@haydenir.com


'/>"/>
SOURCE NewCardio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. NewCardio Leadership to Present Two Abstracts at ISCE Conference
2. Vincent W. Renz Joins NewCardio as President
3. NewCardio Announces Positive Results From Third Clinical Validation Study
4. Amgen Announces Positive Top-Line Results for Denosumab in Trial for Delay of Skeletal Related Events in Bone Metastases Patients Compared to Zometa(R)
5. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
6. Cryo-Cell Announces Celle(SM) Research and Development Collaboration with Cryopraxis Cryobiology Ltd.
7. NeurogesX Announces Preliminary Results of FDA-Requested Qutenza(TM) Study
8. Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma
9. Cardica Announces Publication of Pivotal PAS-Port(R) Proximal Anastomosis System Clinical Trial Results
10. Poniard Pharmaceuticals Announces Positive Cardiac Safety Data From Picoplatin Phase 1 Trial Supporting NDA Filing
11. AlphaVax Announces Results from Initial Testing of Its H1N1 (Swine) Influenza Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... June 24, 2016 Research and Markets ... for Companion Diagnostic Tests" report to their offering. ... Companion Diagnostics The World Market for Companion ... medicine diagnostics. Market analysis in the report includes the following: ... (In Vitro Diagnostic Kits) by Region (N. America, EU, ROW), ...
(Date:6/23/2016)... , June 23, 2016  MedSource announced ... as its e-clinical software solution of choice.  This ... best possible value to their clients by offering ... The preferred relationship establishes nowEDC as the EDC ... for MedSource,s full-service clients.  "nowEDC has long been ...
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is ... associated with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of ...
Breaking Medicine News(10 mins):